Source:http://linkedlifedata.com/resource/pubmed/id/10052405
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
1999-3-22
|
| pubmed:abstractText |
To determine the safety and clinical effects of interleukin 10 (IL-10) treatment of psoriasis.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
0003-987X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
135
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
187-92
|
| pubmed:dateRevised |
2008-3-17
|
| pubmed:meshHeading | |
| pubmed:year |
1999
|
| pubmed:articleTitle |
Interleukin 10 treatment of psoriasis: clinical results of a phase 2 trial.
|
| pubmed:affiliation |
Department of Dermatology, University Hospital Charité, Berlin Humboldt University, Germany.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|